Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-negative Breast Cancer Patients With Brain Metastases”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05323955
What this trial is testing

Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib

Who this might be right for
Brain MetastasesHuman Epidermal Growth Factor 2 Positive Carcinoma of BreastAdvanced Breast Cancer
Carey Anders, M.D. 48
Testing effectiveness (Phase 2)Ended earlyNCT02774681
What this trial is testing

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

Who this might be right for
Breast Carcinoma Metastatic in the BrainEstrogen Receptor NegativeHER2/Neu Negative+4 more
Northwestern University 12
Testing effectiveness (Phase 2)Looking for participantsNCT04348747
What this trial is testing

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Malignant Neoplasm in the BrainMetastatic Triple-Negative Breast Carcinoma+1 more
Roswell Park Cancer Institute 23
Testing effectiveness (Phase 2)Ended earlyNCT01132664
What this trial is testing

Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2+ Breast Cancer
Novartis Pharmaceuticals 72
Testing effectiveness (Phase 2)WithdrawnNCT01913067
What this trial is testing

Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC

Who this might be right for
Brain MetastasisBreast CancerNon Small Cell Lung Cancer
Jules Bordet Institute